Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 2/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.51 |
| ▸ | LTA4H | P09960 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 2/20 | 0.49 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.49 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.49 |
| ▸ | BCHE | P06276 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5123289 | 0.93 | KMT2A (0.55) | KMT2AACHEPRKAA2BCHE | |
| SCHEMBL5116996 | 0.88 | CCR3 (0.53) | KCNH2MEN1KMT2APRKAA2 | |
| SCHEMBL5118829 | 0.88 | MEN1 (0.52) | CHRM4KCNH2MEN1KMT2AACHE | |
| SCHEMBL5110349 | 0.82 | KMT2A (0.47) | MEN1KMT2AACHEBCHE | |
| SCHEMBL5110138 | 0.82 | BCHE (0.51) | KCNH2MEN1KMT2AACHEBCHE | |
| SCHEMBL5116776 | 0.82 | BCHE (0.51) | KCNH2MEN1KMT2AACHEBCHE | |
| SCHEMBL5116779 | 0.82 | BCHE (0.51) | KCNH2MEN1KMT2AACHEBCHE | |
| SCHEMBL5113701 | 0.82 | BCHE (0.51) | KCNH2MEN1KMT2AACHEBCHE | |
| SCHEMBL5124782 | 0.82 | SLC2A1 (0.48) | CHRM4KCNH2SLC2A1LTA4HMEN1 | |
| SCHEMBL5116279 | 0.81 | POLB (0.46) | KCNH2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7351721-B2 | Amino acid derivatives and pharmaceutical composition comprising, as active ingredients, them | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-04-01 | — | — | US | claimed |
| US-7351721-B2 | Amino acid derivatives and pharmaceutical composition comprising, as active ingredients, them | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-04-01 | — | — | US | disclosed |
| US-20030232806-A1 | Amino acid derivatives and pharmaceutical composition comprising, as active ingredients, them | ONO PHARMACEUTICAL CO., LTD. | 2003-12-18 | — | — | US | disclosed |
| US-6605608-B1 | Such as n-(1-benzylpiperidin-4-yl)-3-cyclohexylmethylthio-2-((4R)-3-t -butoxycarbonylthiazolidin-4-ylcarbonylamino)propan-a mide; n-type calcium channel inhibitors | ONO PHARMACEUTICAL CO., LTD (JP) | 2003-08-12 | — | — | US | disclosed |
| EP-1090912-A1 | AMINO ACID DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2001-04-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232806-A1 | Amino acid derivatives and pharmaceutical composition comprising, as active ingredients, them | CACNA1I, CACNA1S, CACNA1B | CHRM4 2286/4885KCNH2 73/4885SLC2A1 1230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.